Krystal Biotech (NASDAQ:KRYS) Shares Gap Down on Disappointing Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS)’s share price gapped down before the market opened on Monday following a weaker than expected earnings announcement. The stock had previously closed at $161.10, but opened at $145.50. Krystal Biotech shares last traded at $156.83, with a volume of 263,735 shares trading hands.

The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.20 by ($0.17). The company had revenue of $45.25 million for the quarter, compared to analyst estimates of $47.37 million. During the same quarter last year, the company earned ($1.76) EPS. The company’s quarterly revenue was up 452400.0% compared to the same quarter last year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $200.00 price target on shares of Krystal Biotech in a report on Monday. William Blair reiterated an “outperform” rating on shares of Krystal Biotech in a research report on Tuesday, February 27th. Guggenheim upped their target price on shares of Krystal Biotech from $130.00 to $175.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Citigroup boosted their target price on Krystal Biotech from $160.00 to $195.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $204.00 target price (up from $178.00) on shares of Krystal Biotech in a report on Tuesday, April 16th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $171.00.

Insider Buying and Selling

In other news, CAO Kathryn Romano sold 5,000 shares of the stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $165.88, for a total value of $829,400.00. Following the completion of the sale, the chief accounting officer now owns 12,936 shares in the company, valued at $2,145,823.68. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the transaction, the insider now directly owns 1,550,882 shares in the company, valued at $265,138,786.72. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CAO Kathryn Romano sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $165.88, for a total value of $829,400.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,936 shares of the company’s stock, valued at approximately $2,145,823.68. The disclosure for this sale can be found here. Insiders sold a total of 38,087 shares of company stock valued at $6,210,591 over the last three months. 14.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its position in shares of Krystal Biotech by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 2,435,774 shares of the company’s stock worth $302,182,000 after purchasing an additional 35,632 shares during the last quarter. Jennison Associates LLC raised its holdings in shares of Krystal Biotech by 112.5% during the fourth quarter. Jennison Associates LLC now owns 724,344 shares of the company’s stock valued at $89,862,000 after purchasing an additional 383,495 shares during the period. Dimensional Fund Advisors LP lifted its stake in Krystal Biotech by 5.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 550,806 shares of the company’s stock valued at $68,337,000 after acquiring an additional 30,169 shares in the last quarter. TimesSquare Capital Management LLC boosted its holdings in shares of Krystal Biotech by 103.6% in the 4th quarter. TimesSquare Capital Management LLC now owns 250,470 shares of the company’s stock worth $31,073,000 after buying an additional 127,435 shares during the last quarter. Finally, First Turn Management LLC purchased a new stake in Krystal Biotech during the fourth quarter valued at about $30,045,000. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Stock Down 2.0 %

The stock has a market capitalization of $4.52 billion, a P/E ratio of 2,022.25 and a beta of 0.91. The company has a 50-day moving average price of $168.87 and a two-hundred day moving average price of $134.11.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).